Document is current
Any future updates will be listed below
-
Authors
Ismailova, Gamida
Wagenmakers, Margreet A. E. M.
Brusse, Esther
van der Ploeg, Ans T.
Favejee, Marein M.
van der Beek, Nadine A. M. E.
van den Berg, Linda E. M. https://orcid.org/0000-0002-8726-1304
-
Funding
Funding for this research was provided by:
Prinses Beatrix Spierfonds (W.OK18-13, 2018)
- License Information
-
More Information
Article History
Received: 10 July 2023
Accepted: 22 September 2023
First Online: 11 October 2023
Declarations
:
: This study was approved by the Ethical Committee at the Erasmus University Medical Centre (NL16769.078.07, V17, Amendment 13). Informed consent was obtained from all patients.
: Not applicable.
: GI, LvdB, EB and MF declare no competing interests. AvdP received funding for clinical research trials and as advisor from Sanofi Genzyme, Amicus Therapeutics, Spark Therapeutics and Denali Therapeutics under agreements with Erasmus University Medical Center and the commercial entity. Payments for advisory services were made to the institution, no personal payments were obtained. AvdP is vice-coordinator at the European Pompe Consortium (EPOC) and MetabERN (European Reference Network), coordinator at Metab ERN-LSD Subnetwork (European Reference Network) and board member of Euro-NMD (European Reference Network). NvdB received funding for clinical research trials and advisory fees from Sanofi Genzyme under agreements with Erasmus University Medical Center and the commercial entity. Payments were made to the institution, no personal payments were obtained. She also received a Veni grant from Zon MW: project no. 09150161910230. MW received funding for clinical research trials from Nutricia Metabolic Research Fund and Moderna under agreements with Erasmus University Medical Center and the commercial entity. Payments were made to the institution, no personal payments were obtained.
